Jump to content

Delucemine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Mandishaa (talk | contribs) at 03:21, 15 May 2018 (replace the dead link for Annual Report). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Delucemine
Clinical data
ATC code
  • none
Identifiers
  • 3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17F2N
Molar mass261.3097 g/mol g·mol−1
3D model (JSmol)
  • CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
  • InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3 ☒N
  • Key:MUGNLPWYHGOJEG-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Delucemine (NPS-1506) is a drug which acts as an NMDA antagonist and a serotonin reuptake inhibitor, and has neuroprotective effects.[1][2] It was originally investigated for the treatment of stroke and in 2004 was studied as a potential antidepressant.[3][4][5]

Origin

The basic structure of Delucemine was based on argiotoxin 636, a NMDA antagonist isolated from the venom of the Araneid Argiope aurantia.[6][7][8]

See also

References

  1. ^ Mueller AL, Artman LD, Balandrin MF, Brady E, Chien Y, Delmar EG, George K, Kierstead A, Marriott TB, Moe ST, Newman MK, Raszkiewicz JL, Sanguinetti EL, van Wagenen BC, Wells D (December 1999). "NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies". Annals of the New York Academy of Sciences. 890: 450–457. doi:10.1111/j.1749-6632.1999.tb08023.x. PMID 10668449.
  2. ^ Matthew J. Leoni; Xiao-Han Chen; Alan L. Mueller; Jessica Cheney; Tracy K. McIntosh; Douglas H. Smith (December 2000). "NPS 1506 attenuates cognitive dysfunction and hippocampal neuron death following brain trauma in the rat". Experimental Neurology. 166 (2): 442–449. doi:10.1006/exnr.2000.7513. PMID 11085909.
  3. ^ "NPS Pharmaceuticals Inc, Form 10-Q, Quarterly Report, Filing Date May 17, 2004". secdatabase.com. Retrieved May 14, 2018.
  4. ^ Robert Pyke, Angelo Ceci. "Patent CA 2599721 A1 - Pharmaceutical compositions for the treatment and/or prevention of depression". Retrieved 24 June 2015.
  5. ^ Fumito Ichinose; Eizo Marutani; Kotaro Kida. "Patent WO 2014015047 A1 - Compositions and methods to treat neurodegenerative diseases". Retrieved 24 June 2015.
  6. ^ Nentwig, Wolfgang (2013-02-15). Spider Ecophysiology. Springer Science & Business Media. ISBN 9783642339899.
  7. ^ Vera Oldrati; Estelle Bianchi; Reto Stöcklin (February 2013). "Spider Venom Components as Drug Candidates". Spider Ecophysiology: 491–503. doi:10.1007/978-3-642-33989-9_37.
  8. ^ Victoria Monge-Fuentes; Flávia Maria Medeiros Gomes; Gabriel Avohay Alves Campos; Juliana de Castro Silva; Andréia Mayer Biolchi; Lilian Carneiro dos Anjos; Jacqueline Coimbra Gonçalves; Kamila Soares Lopes; Márcia Renata Mortari (August 2015). "Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders". Journal of Venomous Animals and Toxins including Tropical Diseases. 21 (31). doi:10.1186/s40409-015-0031-x. PMC 4529710. PMID 26257776.{{cite journal}}: CS1 maint: unflagged free DOI (link)


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Delucemine&oldid=841319314"